Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 13 07 2019
revised: 12 11 2019
accepted: 13 11 2019
pubmed: 26 11 2019
medline: 8 10 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Identifiants

pubmed: 31763708
doi: 10.1111/ejh.13358
pmc: PMC7065130
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating Tumor DNA 0
Immunoglobulin Heavy Chains 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-197

Subventions

Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : AZV 17-29343A

Informations de copyright

© 2019 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

Références

Trends Cancer. 2017 Jan;3(1):1-2
pubmed: 28718422
Cancer Res. 1998 Sep 1;58(17):3957-64
pubmed: 9731509
Haematologica. 2017 Jun;102(6):1105-1111
pubmed: 28183851
Blood Adv. 2018 Nov 13;2(21):2811-2813
pubmed: 30355580
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Biol Blood Marrow Transplant. 2013 Jul;19(7):1109-15
pubmed: 23644045
J Thorac Oncol. 2018 Jan;13(1):112-123
pubmed: 28951314
Nat Commun. 2018 Apr 27;9(1):1691
pubmed: 29703982
Exp Hematol. 2002 Jun;30(6):529-36
pubmed: 12063019
Leukemia. 2017 Aug;31(8):1695-1705
pubmed: 27899805
Chronic Dis Transl Med. 2016 Dec 22;2(4):223-230
pubmed: 29063046
Haematologica. 2018 Jun;103(6):e245-e248
pubmed: 29472358
Bone Marrow Transplant. 2008 Aug;42(3):187-96
pubmed: 18490915
Blood. 2017 Mar 23;129(12):1685-1690
pubmed: 28126926
Exp Hematol. 2015 May;43(5):374-381.e2
pubmed: 25591497
Blood Cancer J. 2017 Dec 5;7(12):639
pubmed: 29209089
Cancer Metastasis Rev. 2017 Dec;36(4):561-584
pubmed: 29196868
Ther Adv Hematol. 2018 May;9(5):123-133
pubmed: 29713445
Nat Commun. 2017 May 11;8:15086
pubmed: 28492226
J Clin Med. 2017 Sep 25;6(10):
pubmed: 28946710
Blood. 2014 May 15;123(20):3073-9
pubmed: 24646471
Leukemia. 2014 Feb;28(2):391-7
pubmed: 23860448
Cancer Biol Med. 2016 Jun;13(2):215-25
pubmed: 27458529
Klin Onkol. 2017 Summer;30(Supplementum2):21-28
pubmed: 28903567
Recent Results Cancer Res. 2011;183:25-35
pubmed: 21509679
Leukemia. 1997 Oct;11(10):1793-8
pubmed: 9324303
Eur J Haematol. 2017 Oct;99(4):291-299
pubmed: 28692178
Cancer. 2007 Aug 15;110(4):896-905
pubmed: 17594697
Br J Haematol. 2013 Oct;163(1):123-6
pubmed: 23795711
Methods Mol Med. 2005;113:145-63
pubmed: 15968100
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Eur J Haematol. 2020 Mar;104(3):190-197
pubmed: 31763708
Future Sci OA. 2018 Feb 23;4(4):FSO295
pubmed: 29682327
Blood Cancer J. 2017 Aug 25;7(8):e590
pubmed: 28841203
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Ann Hematol. 2009 Sep;88(9):897-905
pubmed: 19165483
J Biol Chem. 2016 Mar 11;291(11):5948-59
pubmed: 26786097
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
J Mol Diagn. 2018 Nov;20(6):859-870
pubmed: 30165206
Biol Blood Marrow Transplant. 2000;6(3):241-53
pubmed: 10871149
Leukemia. 2015 Mar;29(3):689-95
pubmed: 25027515
Haematologica. 2014 Mar;99(3):511-8
pubmed: 24241494
Am J Hematol. 2018 Jul;93(7):889-894
pubmed: 29659048
Haematologica. 2005 Oct;90(10):1365-72
pubmed: 16219573
Leukemia. 2007 Apr;21(4):604-11
pubmed: 17287850
Clin Chem Lab Med. 2012 Jan 31;50(6):1139-40
pubmed: 22706262
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Best Pract Res Clin Haematol. 2002 Mar;15(1):197-222
pubmed: 11987924

Auteurs

David Vrabel (D)

Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.

Lenka Sedlarikova (L)

Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.

Lenka Besse (L)

Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Lucie Rihova (L)

Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.

Renata Bezdekova (R)

Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.

Martina Almasi (M)

Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.

Veronika Kubaczkova (V)

Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Lucie Brožová (L)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Hana Plonkova (H)

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Tomas Jelinek (T)

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Viera Sandecka (V)

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Martin Stork (M)

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Ludek Pour (L)

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Sabina Sevcikova (S)

Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Roman Hajek (R)

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH